Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 6/2019

01-06-2019 | Original Paper

Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy

Authors: Ibrahim Ozdemir, Ayla Eren, Giray Ersöz

Published in: International Ophthalmology | Issue 6/2019

Login to get access

Abstract

Purpose

To evaluate a relation between the outer nuclear layer (ONL) thickness and symptom duration in patients with central serous chorioretinopathy (CSC) using spectraldomain optical coherence tomography (SDOCT) and to compare with healthy subjects.

Methods

This retrospective study included 67 CSC patients and 20 healthy subjects. The ONL thickness was measured between internal limiting membrane and external limiting membrane at central fovea using SD-OCT (Topcon 3D OCT-2000, Japan). The patients were divided into six groups based on symptom duration: group (1) contained 14 patients (symptom duration between 1 and 30 days) , group (2) contained 11 patients (symptom duration between 31 and 60 days), group (3) contained 12 patients (symptom duration between 61 and 90 days) , group (4) contained 11 (symptom duration between 91 and 120 days), group (5) contained 7 patients (symptom duration between 121 and 150 days) and group (6) contained 12 (symptom duration between 151 days and more).

Results

The average ONL thickness was 76.1 ± 16.8 μm in CSC in all patients and 122.4 ± 2.8 μm in healthy subjects. The major differences were between group (3) and (4) (p < 0.001). The ONL thickness was negatively correlated with symptom duration (rs = − 0.918; p< 0.001). In addition, the ONL thickness was positively correlated with BCVA (rs = 0.619; p< 0.001).

Conclusion

Photoreceptor loss could begin within the first 3 months in CSC.
Literature
1.
Iida T, Hagimura N, Sato T, Kishi S (2000) Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol 129:16–20CrossRefPubMed
2.
Behar-Cohen F, Zhao M (2016) Corticosteroids and the retina: a role for the mineralocorticoid receptor. Curr Opin Neurol 29:49–54CrossRefPubMed
3.
Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496–500CrossRef
4.
Matsumoto H, Sato T, Kishi S (2009) Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol 148:105–110CrossRefPubMed
5.
Ojima Y, Hangai M, Sasahara M, Gotoh N, Inoue R, Yasuno Y, Makita S, Yatagai T, Tsujikawa A, Yoshimura N (2007) Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 114:2197–2207CrossRefPubMed
6.
Piccolino FC, de la Longrais RR, Ravera G et al (2005) The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 139:87–99CrossRefPubMed
7.
Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133:787–793CrossRefPubMed
8.
Eandi CM, Chung JE, Cardillo-Piccolino F, Spaide RF (2005) Optical coherence tomography in unilateral resolved central serous chorioretinopathy. Retina 25:417–421CrossRefPubMed
9.
Schocket LS, Witkin AJ, Fujimoto JG et al (2006) Ultrahigh-resolution optical coherence tomography in patients with decreased visual acuity after retinal detachment repair. Ophthalmology 113:666–672CrossRefPubMedPubMedCentral
10.
Drexler W, Sattmann H, Hermann B et al (2003) Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 121:695–706CrossRefPubMed
11.
Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRef
12.
Verma L, Sinha R, Venkatesh P et al (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial. BMC Ophthalmol. 4:15CrossRefPubMedPubMedCentral
13.
Chan WM, Lim T-H, Pece A et al (2010) Verteporfin PDT for non-standard indications a review of current literature. Graefes Arch Clin Exp Ophthalmol 248:613–626CrossRefPubMed
14.
Cook B, Lewis GP, Fisher SK et al (1995) Apoptotic photoreceptordegeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 36:990–996PubMed
15.
Hisatomi T, Sakamoto T, Goto Y et al (2002) Critical role of photoreceptor apoptosis in functional damage after retinal detachment. Curr Eye Res 41:1542–1545
16.
Vogel RN, Langlo CS, Scoles D et al (2017) High-resolution imaging of intraretinal structures in active and resolved central serous chorioretinopathy. Invest Ophthalmol Vis Sci 58(1):42–49CrossRefPubMedPubMedCentral
17.
Yannuzzi LA (2010) Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 149:361–363CrossRefPubMed
18.
Chan WM, Lam DSC, Lai TYY et al (2003) Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 136:836–845CrossRefPubMed
19.
Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126CrossRefPubMedPubMedCentral
20.
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096–2102CrossRefPubMed
21.
Pichi F, Carrai P, Ciardella A, Behar-Cohen F, Nucci P (2016) Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 16:377–382
Metadata
Title
Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy
Authors
Ibrahim Ozdemir
Ayla Eren
Giray Ersöz
Publication date
01-06-2019
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 6/2019
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-018-0950-y

Other articles of this Issue 6/2019

International Ophthalmology 6/2019 Go to the issue

Letter to the Editor

Ocular surface squamous neoplasia in a setting of fungal keratitis: a rare co-occurrence

Original Paper

Comparison of pain after subepithelial versus conventional accelerated corneal collagen cross-linking for keratoconus

Original Paper

Structural changes of macula and optic disk of the fellow eye in patients with nonarteritic anterior ischemic optic neuropathy

Original Paper

A study of changes in levator muscle in congenital ptosis

Original Paper

Hook and flip technique: for phacoemulsification in non-rotating nuclei and posterior polar cataracts

Original Paper

Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinson’s disease